- Current report filing (8-K)
November 14 2011 - 8:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): November 7, 2011
Gen-Probe Incorporated
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-49834
|
|
33-0044608
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
10210 Genetic Center Drive
San Diego, CA
|
|
92121
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(858) 410-8000
(Registrants telephone number, including area code)
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
The following disclosure is provided pursuant to subsections (b) and (e) of Item 5.02 of Form
8-K.
On November 7, 2011, Eric Lai, Ph.D. resigned from his employment as Senior Vice President, Research and
Development of Gen-Probe Incorporated (the Company). In connection with Dr. Lais resignation, the Company and Dr. Lai entered into a separation agreement pursuant to which Dr. Lai will receive (a) continued
compensation at Dr. Lais current base salary (less applicable tax withholdings) and employer-funded costs of Dr. Lais current life insurance coverage under the Companys life insurance plan, in each case through
November 7, 2012, (b) a lump sum cash payment representing Dr. Lais estimated bonus payment under the Companys 2011 Employee Bonus Plan, pro-rated through the date of his resignation, (c) continued health care
coverage for Dr. Lai and his eligible dependents under the Companys health plan through the earlier of November 7, 2012 or the first date that Dr. Lai is covered under another employers health benefit program providing
substantially the same or better benefits, and (d) outplacement services for six months. The Company and Dr. Lai have agreed that performance of the separation agreement by the Company will satisfy all of the Companys
obligations to Dr. Lai in connection with his employment.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: November 14, 2011
|
|
|
|
|
|
GEN-PROBE INCORPORATED
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ R. William Bowen
|
|
|
|
|
|
|
R. William Bowen
|
|
|
|
|
|
|
Senior Vice President, General Counsel and
|
|
|
|
|
|
|
Secretary
|
3
GoPro (NASDAQ:GPRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
GoPro (NASDAQ:GPRO)
Historical Stock Chart
From Jul 2023 to Jul 2024